Matches in SemOpenAlex for { <https://semopenalex.org/work/W2951208183> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- W2951208183 abstract "Aim of review. To present literature data on administration of vedolizumab at inflammatory bowel diseases. Summary. The vedolizumab is anti-α4β7-integrin humanized class IgG1 antibodies which suppresses migration of leukocytes in intestinal tissue, interfering thereby with development of pathologic inflammation. GEMINI-1 study of ulcerative colitis has demonstrated efficacy of the drug in remission induction (clinical response rate of 47,1% of patients, clinical remission of 16,9% and endoscopic remission of 40,9% at the 6th week) and in remission maintenance (percent of patients in clinical remission at 52nd week at drug injection every 4 weeks - 44,8%). Similar efficacy was demonstrated for Crohn's disease (GEMINI-2) study in remission induction (clinical response rate - 31,4% of patients, clinical remission - 14,5%) and remission maintenance (percentage of patient in clinical remission by 52nd week at injection of the drug every 4 weeks - 39%). The results received in clinical trials were confirmed by clinical data in the different countries. Safety profile investigations demonstrated low system immune suppression due to specific action mechanism of the drug. Besides, due to α4β7 integrin heterodimer selectivity of vedolizumab, it provides selective block of intestinal leukocyte migration, without affection of central nervous system therefore the risk of the progressing multifocal leukoencephalopathy is not established. Conclusion. Present clinical trials has demonstrated that vedolizumab is effective and safe in treatment of inflammatory bowel diseases." @default.
- W2951208183 created "2019-06-27" @default.
- W2951208183 creator A5063541114 @default.
- W2951208183 creator A5083356840 @default.
- W2951208183 date "2018-08-01" @default.
- W2951208183 modified "2023-09-27" @default.
- W2951208183 title "Vedolizumab for inflammatory bowel diseasesI" @default.
- W2951208183 doi "https://doi.org/10.22416/1382-4376-2016-26-6-92-100" @default.
- W2951208183 hasPublicationYear "2018" @default.
- W2951208183 type Work @default.
- W2951208183 sameAs 2951208183 @default.
- W2951208183 citedByCount "0" @default.
- W2951208183 crossrefType "journal-article" @default.
- W2951208183 hasAuthorship W2951208183A5063541114 @default.
- W2951208183 hasAuthorship W2951208183A5083356840 @default.
- W2951208183 hasConcept C126322002 @default.
- W2951208183 hasConcept C2776207728 @default.
- W2951208183 hasConcept C2777572184 @default.
- W2951208183 hasConcept C2778260677 @default.
- W2951208183 hasConcept C2779134260 @default.
- W2951208183 hasConcept C71924100 @default.
- W2951208183 hasConcept C90924648 @default.
- W2951208183 hasConceptScore W2951208183C126322002 @default.
- W2951208183 hasConceptScore W2951208183C2776207728 @default.
- W2951208183 hasConceptScore W2951208183C2777572184 @default.
- W2951208183 hasConceptScore W2951208183C2778260677 @default.
- W2951208183 hasConceptScore W2951208183C2779134260 @default.
- W2951208183 hasConceptScore W2951208183C71924100 @default.
- W2951208183 hasConceptScore W2951208183C90924648 @default.
- W2951208183 hasLocation W29512081831 @default.
- W2951208183 hasOpenAccess W2951208183 @default.
- W2951208183 hasPrimaryLocation W29512081831 @default.
- W2951208183 hasRelatedWork W2328584717 @default.
- W2951208183 hasRelatedWork W2660092592 @default.
- W2951208183 hasRelatedWork W2790228140 @default.
- W2951208183 hasRelatedWork W2794344940 @default.
- W2951208183 hasRelatedWork W2888701558 @default.
- W2951208183 hasRelatedWork W3166003727 @default.
- W2951208183 hasRelatedWork W4230207006 @default.
- W2951208183 hasRelatedWork W4232531751 @default.
- W2951208183 hasRelatedWork W4282931889 @default.
- W2951208183 hasRelatedWork W4287877683 @default.
- W2951208183 isParatext "false" @default.
- W2951208183 isRetracted "false" @default.
- W2951208183 magId "2951208183" @default.
- W2951208183 workType "article" @default.